Clinical Trial Update: Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating balugrastim in pediatric patients with solid tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Balugrastim (Balugrastim)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Solid Tumors | Phase 2 | Status: WITHDRAWN